LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Home・Elenco Azioni・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Aperta

SettoreSettore sanitario

155.43 1.89

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

151.1

Massimo

155.35

Metriche Chiave
By Trading Economics
Entrata	-89M -454M
EPS	-2.29
Dipendenti	883
EBITDA	-92M -441M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+21.37% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	3.4B 35B
Apertura precedente	153.54
Chiusura precedente	155.43

Notizie sul Sentiment di mercato

By Acuity

50%

147 / 344 Classifica in Healthcare

REVOLUTION Medicines Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 gen 2026, 11:10 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 gen 2026, 20:13 UTC

I principali Market Mover

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 ott 2025, 18:13 UTC

I principali Market Mover

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 gen 2026, 09:55 UTC

Azioni calde

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 gen 2026, 19:58 UTC

Acquisizioni, Fusioni, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 gen 2026, 14:54 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 gen 2026, 10:54 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 gen 2026, 14:49 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 gen 2026, 12:38 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 gen 2026, 20:29 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Has Market Value of Around $16B -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Near Deal for Revolution Medicines -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

Deal May Come Soon, Sources Say -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Confronto tra pari

Modifica del prezzo

REVOLUTION Medicines Inc Previsione

Obiettivo di Prezzo

By TipRanks

21.37% in crescita

Previsioni per 12 mesi

Media 183.65 USD 21.37%

Alto 263 USD

Basso 140 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 21 che hanno fornito valutazioni azionarie a REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

147 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.